The US-based clinical-stage medical device company, TECLens, has closed a $10 million Series A2 extension financing to support clinical development of its quantitative corneal cross-linking (qCXL) platform for non-invasive refractive vision correction.
The financing includes participation from existing investors, including Johnson & Johnson through its corporate venture capital arm, Johnson & Johnson Innovation. According to TECLens, the proceeds will support continued expansion of its first-in-human proof-of-concept program, generation of additional clinical data, development of its next-generation system, and preparation for a future investigational device exemption submission.
The funding follows the launch earlier this year of TECLens’ first-in-human proof-of-concept study evaluating qCXL for refractive vision correction. The company said the financing round was subsequently expanded following additional investor interest.
TECLens’ CXLens System is designed to reshape the cornea using personalized patterns of ultraviolet light without cutting or removing corneal tissue. The technology uses corneal cross-linking to create molecular bonds in selected areas of the cornea, with the aim of producing controlled changes in corneal shape.
The system combines a proprietary treatment-planning engine with real-time ultrasound monitoring intended to guide delivery of each individualized treatment.
The ongoing proof-of-concept study is evaluating the approach in patients with refractive errors, with a particular focus on presbyopia.
“This financing reflects the significant progress TECLens has made in advancing our proof-of-concept clinical study and the growing confidence in our technology,” said Madhu Ayyagari, CEO of TECLens.
Ayyagari, who became CEO of the company in June 2026, bringing extensive experience from his medtech innovation and company development background, added that the additional funding would allow the company to expand its clinical program and continue advancing the platform toward a “fundamentally different approach to refractive vision correction.”
TECLens is presenting updates from its clinical development program at the ESCRS meeting in London (September 11-15), and at the American Academy of Ophthalmology annual meeting in New Orleans later this year.
Source: TECLens.
